On October 7, 2020, Scribe Therapeutics announced a collaboration with Biogen, to collaborate on CRISPR-based medicines for treating neurological diseases, and specifically Amyotrophic Lateral Sclerosis. That deal is valued at $15 million in upfront commitments, with as much as $400 million or more in milestone payouts to follow, as well as royalties attached to any shipping therapeutics that result.
Scribe was founded by genome and molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Nobel-prize winner Jennifer Doudna to move beyond the issues of safety, delivery, poor editing outcomes, and an uncertain intellectual property landscape that limit current CRISPR technology. With an unmatched expertise and track record in CRISPR and protein engineering, the Scribe team is building and applying a suite of CRISPR technologies designed for therapeutic use, into a single continually evolving and expanding genetic modification platform.
Scribe is focused on engineering an advanced platform for CRISPR-based genetic medicine. On October 6, 2020, Scribe unveiled its vision for highly efficient and specific in vivo genome modification. Since launching out of UC Berkeley’s Doudna Lab, Oakes Lab, and the Innovative Genomics Institute in late 2018, Scribe utilized an initial $20 million Series A round of funding from Andreessen Horowitz and additional investors to further develop a custom platform of gene editing and delivery technologies that will revolutionize genetic medicine.